Uttarakhand Suspends Permissions Of 14 Products Of Ramdev’s Pharma Firms

Haridwar: An Indian state regulator has suspended manufacturing licences of 14 products made by pharmaceutical companies of the country’s most popular yoga guru for repeatedly publishing misleading advertisements about their efficacy, a government order showed.

The order is the latest setback for Baba Ramdev whose TV shows, yoga cures and traditional medicine offerings for diseases have made him popular in India and other nations.

The Supreme Court of India has in recent weeks repeatedly criticised Ramdev for not complying with its directives in an ongoing lawsuit to stop misleading advertisements of some of his traditional ayurvedic medicines.

The manufacturing permits of Ramdev’s companies were suspended in an April 15 order by the drug regulator of traditional medicines in northern Uttarakhand state. Reuters is the first to report the order which is not public.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

Related Posts

  • Pharma
  • February 17, 2025
  • 86 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 74 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%